Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA-binding protein 28 (RBM28) is a specific nucleolar component of the spliceosomal small nuclear ribonucleoprotein complexes, uniquely associating with multiple snRNAs (U1, U2, U4, U5, U6) and potentially coordinating their transition through the nucleolus[1][5][3]. It responds to nucleolar stress and may move between cellular compartments to modulate the activity of proteins such as p53[9]. Mutations in RBM28 are associated with a rare syndrome characterized by alopecia, neurological defects, and endocrinopathies (ANE syndrome)[1][3]. There is no evidence that RBM28 is a direct target for current therapeutic drugs, nor are any biomarkers or mechanisms of drug action documented for this protein[3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA-binding protein 28 (RBM28).